Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Abstract In the primary analysis (32.3-month median follow-up) of the randomized, phase 3 AURIGA study (NCT03901963), daratumumab-lenalidomide (D-R) maintenance significantly improved MRD-negative conversion rates and reduced the risk of disease progression or death by 47% versus R maintenance in an...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Laahn Foster, Larry D. Anderson, Alfred Chung, Chakra P. Chaulagain, Erin Pettijohn, Andrew J. Cowan, Caitlin Costello, Sarah Larson, Douglas W. Sborov, Kenneth H. Shain, Rebecca Silbermann, Peter Voorhees, Maria Krevvata, Huiling Pei, Sharmila Patel, Vipin Khare, Annelore Cortoos, Robin Carson, Thomas S. Lin, Ashraf Badros
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2025-10-01
Seri Bilgileri:Blood Cancer Journal
Online Erişim:https://doi.org/10.1038/s41408-025-01355-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller